<DOC>
	<DOCNO>NCT02589977</DOCNO>
	<brief_summary>Unlike heart failure reduce ejection fraction ( HFrEF ) several medicine device demonstrate reduce mortality , therapy identify HFpEF . This may part due incomplete understand underlying mechanism HFpEF . Recently , impaired myocardial blood flow , reduce myocardial energy utilization , increase myocardial fibrosis postulate play important pathophysiologic role HFpEF . The investigator others demonstrate HFrEF may associate altered myocardial energy utilization `` energy starvation . '' However , limited data regard `` energy starvation '' HFpEF relationships myocardial blood flow , energy utilization , fibrosis HFpEF largely unknown . Therefore , purpose study use non-invasive cardiac imaging technique describe cardiac structure , function , blood flow , energetics , fibrosis , relationship order well understand underlie mechanism HFpEF .</brief_summary>
	<brief_title>Myocardial Perfusion , Oxidative Metabolism , Fibrosis HFpEF</brief_title>
	<detailed_description>The investigator hypothesize HFpEF associate reduction myocardial blood flow energy utilization increase myocardial fibrosis compare age gender match hypertensive healthy control . The investigator test hypothesis compare measurement myocardial blood flow , energy utilization , fibrosis three subject group ( HFpEF vs hypertension v healthy ) . Myocardial blood flow quantitated nitrogen ( N ) 13-Ammonia positron emission tomography ( PET ) gadolinium enhance cardiac magnetic resonance ( CMR ) imaging , rest stress follow coronary vasodilation regadenoson . Myocardial energy utilization quantify 11C-acetate PET image myocardial fibrosis assess gadolinium enhance CMR alteration myocardial T1 . Echocardiography utilized quantify cardiac diastolic function . It anticipate result propose study provide foundation inform future study aim identify novel preventive therapeutic agent HFpEF .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<mesh_term>Regadenoson</mesh_term>
	<criteria>ALL estimate glomerular filtration rate ( eGFR ) &gt; 60 ml/min preserve leave ventricular ejection fraction ( &gt; = 50 % ) echocardiography coronary artery disease diabetes mellitus contraindication cardiac magnetic resonance imaging ( CMR ) weight &gt; 350 lbs inability lie flat image anemia contraindication regadenoson aminophylline HEALTHY Inclusion criterion : normal cardiac structure function echocardiography BP &lt; 140/90 Exclusion criterion : know cardiovascular disease , cardiac risk factor use cardiac medication HYPERTENSIVE Inclusion criterion : history BP &gt; 140/90 1 antihypertensive medication LV ejection fraction ( LVEF ) least 50 % current BP &lt; 160/90 Exclusion criterion : know cardiovascular disease risk factor aside hypertension use cardiac medication HFpEF Inclusion criterion : physicianconfirmed diagnosis HF symptomatic HF LVEF least 50 % elevate LV filling pressure catheterization , echocardiographic criterion Btypenatriuretic peptide &gt; 100 current BP &lt; 160/90 Exclusion criterion : prior history LVEF 50 % acute decompensated HF moderate great valvular disease significant cardiac arrhythmia pericardial disease congenital heart disease primary pulmonary hypertension</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>magnetic resonance imaging</keyword>
	<keyword>positron-emission tomography</keyword>
	<keyword>echocardiography</keyword>
	<keyword>myocardial blood flow</keyword>
	<keyword>energy metabolism</keyword>
</DOC>